Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Ondine Biomedical assessing Steriwave with Yorkshire partners
(Sharecast News) - Ondine Biomedical announced on Tuesday that it is joining forces with the Mid Yorkshire Teaching NHS Trust, Health Innovation Yorkshire and Humber, and the York Health Economics Consortium (YHEC) to assess the potential cost savings associated with using its 'Steriwave' technology. The AIM-traded firm said the focus of the evaluation was on reducing the incidence of surgical site infections (SSIs), a major healthcare challenge within the NHS.
SSIs represent a significant strain on the NHS, afflicting one in every 20 surgical patients.
The infections can cause individual costs of up to £0.1m per patient, with the overall economic burden on NHS England exceeding £2bn annually.
Rising antimicrobial resistance (AMR) was threatening to further escalate the costs as standard antibiotic treatments, like mupirocin, became less effective.
Ondine said Steriwave offered a promising alternative approach, using a photosensitizer that, when activated by a specific wavelength of red light, eliminates harmful pathogens within the nose - a known reservoir for infection-causing bacteria like Staphylococcus aureus and MRSA.
The painless, five-minute treatment prevents the spread of the pathogens, including superbugs, without contributing to the growing problem of antimicrobial resistance.
Ondine said the YHEC, known for its expertise in health economics evaluations, would lead the economic analysis alongside an ongoing Steriwave pilot study at the Mid Yorkshire Teaching NHS Trust.
The pilot involved 500 patients undergoing elective hip and knee surgeries over a six-month period, with the analysis aiming to supplement the pilot's findings and further support the wider adoption of Steriwave across the NHS.
Ondine said Steriwave had already gained traction in major Canadian hospitals including the Vancouver General Hospital, the Ottawa Hospital, and the Mazankowski Alberta Heart Institute.
A recent study by VGH, published in the Canadian Journal of Surgery, demonstrated a 66.5% reduction in post-surgical infection rates following the use of Steriwave in spine surgery patients.
The study also highlighted significant cost savings of $2.5m annually.
Ondine said to date there had been no reports of serious adverse events associated with Steriwave treatment.
At 1154 GMT, shares in Ondine Biomedical were flat at 9.4p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.